Treatment for Lysosomal Storage Disorders

Author(s): Jayesh Sheth*, Aadhira Nair*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 40 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Lysosomal storage disorders comprise a group of approximately 70 types of inherited diseases resulting due to lysosomal gene defects. The outcome of the defect is a deficiency in either of the three: namely, lysosomal enzymes, activator protein, or transmembrane protein, as a result of which there is an unwanted accumulation of biomolecules inside the lysosomes. The pathophysiology of these conditions is complex affecting several organ systems and nervous system involvement in a majority of cases. Several research studies have well elucidated the mechanism underlying the disease condition leading to the development in devising the treatment strategies for the same. Currently, these approaches aim to reduce the severity of symptoms or delay the disease progression but do not provide a complete cure. The main treatment methods include Enzyme replacement therapy, Bone marrow transplantation, Substrate reduction therapy, use of molecular chaperones, and Gene therapy. This review article presents an elaborate description of these strategies and discusses the ongoing studies for the same.

Keywords: Lysosomes, Lysosomal storage disorders, enzyme, transplantation, chaperones, gene therapy, ERT, BMT, SRT.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 40
Year: 2020
Published on: 27 November, 2020
Page: [5110 - 5118]
Pages: 9
DOI: 10.2174/1381612826666201015154932
Price: $65

Article Metrics

PDF: 30